Unable to post the entire article so here's the link. GLTA
https://www.adviceforinvestors.com/news/canadian-stocks/2-healthcare-stocks-to-buy-2/#gsc.tab=0
2 healthcare stocks to buy
A medical devices and instruments developer and a healthcare provider and services stock were recently profiled in The MoneyLetter.
Profound Medical Corp. (TSX—PRN)
Douglas Loe and Siew Ching Yeo of Leede Jones Gable assert that a stable list of legacy partnerships, access to liquid assets and new contracts for the TULSA-PRO ultrasound platform will help Profound Medical Corp. weather pandemic challenges apparent in the company’s fourth-quarter results.
Despite a lack of capital-equipment sales in the fourth quarter, the analysts perceive budding growth for the ultrasound-tissue-ablation-device developer and maintain their Buy recommendation.
Profound reported top-line revenue at US$1 million for the quarter, compared to US$2.9 million in fourth-quarter 2020. The company also reported fourth-quarter operating expenses of US$10.2 million, and research and development (R&D) expenses of US$4.7 million.
The company exited the quarter with US$67.2 million in cash and equivalents, which the analysts say is ample funding for approximately two years of ongoing marketing and reimbursement activities for Profound’s TULSA-PRO and Sonalleve devices.
TULSA-PRO is a medical resonance (MR) guided prostate-focused ultrasound ablation platform approved by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA). Sonalleve is a MR-guided prostate-focused ultrasound ablation device which is FDA-approved to treat a niche oncology indication, according to the analysts. The analysts expect positive regional-adoption of the Sonalleve device, but say that sales activity in China, where the device was originally approved, have been affected by the pandemic.
Dentalcorp Holdings Ltd. (TSX—DNTL)
Messrs. Stephen MacLeod and Nevan Yochim of BMO Capital Markets are resuming coverage of healthcare stock Dentalcorp Holdings Inc. with the message that the company demonstrates an attractive risk-to-reward ratio in its expansion plan.